Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) is a global biopharmaceutical leader developing life-changing therapies for complex conditions in oncology, neuroscience, and sleep medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate milestones, regulatory developments, and clinical research advancements.
Our curated collection features official press releases, earnings reports, and analysis of strategic initiatives. Users can track key updates including FDA regulatory decisions, clinical trial results, and therapeutic portfolio expansions. The resource prioritizes accuracy and comprehensiveness, serving as a primary source for understanding Jazz's market position.
Content spans multiple categories essential for informed decision-making: product approvals, research collaborations, financial performance, and manufacturing updates. Each entry maintains strict editorial standards to ensure relevance to both clinical and investment communities.
Bookmark this page for streamlined access to Jazz Pharmaceuticals' latest developments. Check regularly for updates on innovative therapies addressing narcolepsy, epilepsy, and hematologic malignancies, supported by the company's established R&D expertise.
Jazz Pharmaceuticals announced top-line results from the Phase 3 RELEASE MSS1 trial evaluating nabiximols oromucosal spray (JZP378) for multiple sclerosis spasticity. The trial did not meet its primary endpoint of changing Lower Limb Muscle Tone-6 at Day 21. Despite this setback, Jazz remains committed to the nabiximols program, with plans to present data at a future medical meeting. The ongoing Phase 3 trials, RELEASE MSS3 and RELEASE MSS5, aim to supplement this data. Nabiximols has been approved in 29 countries but is not yet FDA-approved in the U.S.
Jazz Pharmaceuticals announced positive results from a Phase 2/3 trial of Rylaze (asparaginase erwinia chrysanthemi) in treating acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). Conducted in collaboration with the Children's Oncology Group, the trial showed that over 90% of patients achieved clinically meaningful nadir serum asparaginase activity. The findings support a new intramuscular dosing schedule aligned with current clinical practices. Rylaze, approved in 2021 for patients with hypersensitivity to E. coli-derived asparaginase, is set to enhance treatment options.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in the Jefferies Healthcare Conference on June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST in New York. An audio webcast of the presentation will be accessible via the Jazz Pharmaceuticals website, with a replay available for 30 days. Jazz Pharmaceuticals is committed to developing innovative treatments for serious diseases and operates globally, serving nearly 75 countries. For more details, visit their official site or follow @JazzPharma on Twitter.
Jazz Pharmaceuticals announced the presentation of 17 new abstracts at SLEEP 2022, from June 4-8, 2022, highlighting advancements in research related to narcolepsy and idiopathic hypersomnia. Key presentations include efficacy analyses of Xywav, a treatment for idiopathic hypersomnia, and interim data from ongoing studies. The research aims to enhance patient understanding and care for these severe sleep disorders, reflecting Jazz's commitment to addressing unmet needs in sleep medicine.
Jazz Pharmaceuticals will present seven abstracts at the ASCO Annual Meeting from June 3-7, 2022, and eight at the EHA Congress from June 9-12, 2022. Key data includes findings on Rylaze in treating acute lymphoblastic leukemia and lymphoblastic lymphoma. An oral presentation will cover the efficacy and safety of Rylaze administered intramuscularly, while several posters will feature data on Zepzelca, Vyxeos, and other therapies. The presentations reflect Jazz's commitment to addressing unmet patient needs in oncology through research advancement.
Axsome Therapeutics has completed the U.S. acquisition of Sunosi (solriamfetol) from Jazz Pharmaceuticals, enhancing its CNS product portfolio. Sunosi, approved by the FDA for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, boasts broad insurance coverage for 96% of commercial lives. The acquisition positions Axsome as a commercial neuroscience company, supporting patient access through comprehensive affordability programs. Clinical trials have shown significant efficacy for Sunosi, including up to 22% reduction in daytime sleepiness and increased wakefulness. Axsome plans further research into Sunosi.
Jazz Pharmaceuticals has successfully completed the divestiture of Sunosi (solriamfetol) in the U.S. to Axsome Therapeutics for an upfront payment of $53 million. Jazz will receive royalties of high single-digit on U.S. net sales for current indications and mid-single-digit for future indications. This transaction allows Jazz to focus on strategic areas for sustainable growth, as stated by CEO Bruce Cozadd. The ex-U.S. transaction is expected to close within 60 days, enhancing Jazz's commitment to operational excellence and shareholder value.
Jazz Pharmaceuticals (JAZZ) announced strong financial results for Q1 2022, reporting $813.7 million in total revenues, a 34% increase year-over-year. The company raised its full-year revenue guidance to $3.5 to $3.7 billion, citing momentum from recent product launches like Xywav for narcolepsy and idiopathic hypersomnia. The net income was $1.6 million ($0.03 per share), significantly lower than $121.8 million from a year earlier. Strategic divestitures and new product developments are set to enhance the company's focus and long-term value.
Jazz Pharmaceuticals has secured exclusive rights to develop and commercialize DSP-0187 in the U.S., Europe, and other regions through a licensing agreement with Sumitomo Pharma. The agreement includes a $50 million upfront payment and up to $1.09 billion in milestone payments. Jazz aims to expedite the development of DSP-0187, a novel oral orexin-2 receptor agonist for treating narcolepsy and other sleep disorders. This collaboration aligns with Jazz's commitment to innovation in sleep medicine, leveraging its expertise in delivering therapies that enhance patient care.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its participation in the BofA Securities 2022 Global Healthcare Conference on May 10, 2022, at 12:40 p.m. PT / 3:40 p.m. ET in Las Vegas. An audio webcast will be available on the Investor section of their website, with a replay archived for 30 days. Jazz Pharmaceuticals is dedicated to developing innovative medicines in neuroscience and oncology, serving patients in nearly 75 countries. For more details, visit www.jazzpharmaceuticals.com.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
